NCT05980728尚未招募不适用
The Prognostic Value of Biomarker in Connective Tissue Disease Patients With Pulmonary Hypertension
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 500
- 主要终点
- Death
研究概览
简要总结
Adult patients with suspected or confirmed Connective Tissue Disease Patients (CTD)With Pulmonary Hypertension(PH)will be recruited. Patients will be approached, consented, have baseline demographics, diagnostics and disease activity measures recorded, and blood taken. The collection of data and biological material will mirror usual clinical practice as far as possible. Subjects will ideally attend further visits at 3, 6 and 12 months to have bloods taken, outcome measures recorded and questionnaires completed.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Definite diagnosis of CTD included Systemic lupus erythematosus（SLE） diagnosed according to the 2019 The European Alliance of Associations for Rheumatology（EULAR） criteria, primary Sjogren's syndrome (pSS) defined according to the 2016 American College of Rheumatology(ACR) criteria, Systemic Sclerosis(SSc) defined according to the 2013 ACR criteria, mixed connective tissue disease (MCTD) defined by Sharp criteria, and Rheumatoid Arthritis(RA) defined according 2010 ACR criteria of two or more CTD at the same time were defined as having overlap syndrome (OS). Patients who had clinical and serological manifestations suggestive of systemic autoimmune diseases but did not fulfil the classification criteria for CTD were defined as having undifferentiated CTD (UCTD).
- •PAH was diagnosed by right heart catheterization was defined as mean Pulmonary Artery Pressure (mPAP)>20 Millimeters of mercury（mmHg）, Pulmonary Artery Wedge Pressure（PAWP）≤15mmHg, Pulmonary Vascular Resistance（PVR）>2 Wood
排除标准
- •significant interstitial lung disease or chronic obstructive pulmonary disease;
- •left heart disease or congenital heart disease associated with pulmonary hypertension;
- •chronic thromboembolic pulmonary hypertension;
- •portal hypertension;
- •drug or toxin exposure;
- •HIV infection;
- •any other diseases known to be associated with PAH;
- •age<18 years.
结局指标
主要结局
Death
时间窗: 30 years
number of participants with All cause death
次要结局
- Clinical worsening(30 years)
研究者
相似试验
已完成
不适用
Significance of Biological Markers in Patients With Acute Lung Injury/Acute Respiratory DiseaseRespiratory Distress Syndrome, AdultNCT00217880University of Michigan40
招募中
不适用
Diagnostic and Prognostic Value of Cardiac Biomarkers for Early Coronary Bypass Occlusion in Patients Undergoing Coronary RevascularizationCoronary Bypass Graft OcclusionNCT04595630University Hospital, Basel, Switzerland480
已完成
不适用
Hemodynamic Changes in Connective Tissue DiseaseSystemic SclerosisNCT01468792Medical University of Graz85
招募中
不适用
Chronic Thromboembolic Pulmonary Hypertension After Pulmonary EmbolismChronic Thromboembolic Pulmonary HypertensionNCT06081881Ester Ashraf Faried Beshay100
已完成
不适用
Cardiac Biomarkers and Mortality in Critically Ill Patients With SARS-CoV-2 (COVID-19)COVID-19NCT04641988University Hospital, Montpellier111